A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 25, 2024
app pub date -
Mar 17, 2022
filing date -
Mar 17, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully